Dr. Tagawa on 2 radiopharmaceuticals for prostate cancer with a proven survival advantage
In this video, Scott T. Tagawa, MD, MS, FACP, discusses the alpha emitter radium-223 dichloride (Xofigo) and the PSMA targeted therapy lutetium Lu 177 vipivotide tetraxetan (Pluvicto), 2 FDA-approved radiopharmaceutical therapies that have proven survival advantages for patients with prostate cancer. Tagawa is an associate professor of clinical medicine and clinical urology and medical director of the Genitourinary Oncology Research Program at Weill Cornell Medicine in New York City. He is also an assistant attending physician on the Cornell campus at New York-Presbyterian Hospital.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
